Impact of Compression Therapy on Cellulitis (ICTOC) in Adults with Chronic Oedema: a Randomised Controlled Trial Protocol

Overview

Journal BMJ Open

Specialty General Medicine

Date 2019 Aug 18

PMID 31420389

Citations 2

Authors

Elizabeth Webb

Teresa Neeman

Jamie Gaida

Francis J Bowden

Virginia Mumford

Bernie Bissett

Affiliations

Soon will be listed here.

Abstract

Introduction: Cellulitis represents a significant burden to patients' quality of life (QOL) and cost to the healthcare system, especially due to its recurrent nature. Chronic oedema is a strong risk factor for both an initial episode of cellulitis and cellulitis recurrence. Expert consensus advises compression therapy to prevent cellulitis recurrence in individuals with chronic oedema, however, there is little supporting evidence. This research aims to determine if the management of chronic oedema using compression therapy effectively delays the recurrence of lower limb cellulitis.

Methods And Analysis: A randomised controlled trial with cross-over will be used to assess the impact of compression therapy on clinical outcomes (time to next episode of cellulitis, rate of cellulitis-related hospital presentations, QOL and leg volume). Using concealed allocation, 162 participants will be randomised into the intervention (compression) or control (no compression) group. Randomisation will be stratified by prophylactic antibiotic use. Participants will be followed up at 6 monthly intervals for up to 3 years or until 45 episodes of cellulitis occur across the cohort. Following an episode of recurrent cellulitis, control group participants will cross-over to the intervention group. Survival analysis will be undertaken to assess the primary outcome measure of time to cellulitis recurrence. The hypotheses are that compression therapy to control lower limb chronic oedema will delay recurrent lower limb cellulitis, reduce the rate of associated hospitalisations, minimise affected limb volume and improve the QOL of this population.

Ethics And Dissemination: Ethics approval has been obtained from the ethics committees of all relevant institutions. Results will be disseminated through relevant peer-reviewed journal articles and conference presentations.

Trial Registration Number: ACTRN12617000412336; Pre-results. The ICTOC trial is currently in progress. Participant recruitment started in May 2017 and is expected to continue until December 2019.

Citing Articles

Predictors of the Efficacy of Lymphedema Decongestive Therapy.

Dzupina A, Yaluri N, Singh J, Jankajova M Medicina (Kaunas). 2025; 61(2).

PMID: 40005348 PMC: 11857323. DOI: 10.3390/medicina61020231.

Compression Therapy Is Cost-Saving in the Prevention of Lower Limb Recurrent Cellulitis in Patients with Chronic Edema.

Webb E, Bissett B, Neeman T, Bowden F, Preston E, Mumford V Lymphat Res Biol. 2022; 21(2):160-168.

PMID: 35997601 PMC: 10125391. DOI: 10.1089/lrb.2022.0029.

Lymphaticovenular anastomosis for recurrent cellulitis in a dementia patient with lymphedema.

Yoshida S, Koshima I, Imai H, Sasaki A, Nagamatsu S, Yokota K J Vasc Surg Cases Innov Tech. 2020; 6(3):340-343.

PMID: 32715167 PMC: 7371726. DOI: 10.1016/j.jvscit.2020.06.007.

References

Dupuy A, Benchikhi H, Roujeau J, Bernard P, Vaillant L, Chosidow O . Risk factors for erysipelas of the leg (cellulitis): case-control study. BMJ. 1999; 318(7198):1591-4. PMC: 28138. DOI: 10.1136/bmj.318.7198.1591. View

Cox N, Colver G, Paterson W . Management and morbidity of cellulitis of the leg. J R Soc Med. 2000; 91(12):634-7. PMC: 1296982. DOI: 10.1177/014107689809101206. View

Carratala J, Roson B, Fernandez-Sabe N, Shaw E, del Rio O, Rivera A . Factors associated with complications and mortality in adult patients hospitalized for infectious cellulitis. Eur J Clin Microbiol Infect Dis. 2003; 22(3):151-7. DOI: 10.1007/s10096-003-0902-x. View

Swartz M . Clinical practice. Cellulitis. N Engl J Med. 2004; 350(9):904-12. DOI: 10.1056/NEJMcp031807. View

Man I, Markland K, Morrissey M . The validity and reliability of the Perometer in evaluating human knee volume. Clin Physiol Funct Imaging. 2004; 24(6):352-8. DOI: 10.1111/j.1475-097X.2004.00577.x. View

Mortimer P, Levick J . Chronic peripheral oedema: the critical role of the lymphatic system. Clin Med (Lond). 2004; 4(5):448-53. PMC: 5351904. DOI: 10.7861/clinmedicine.4-5-448. View

Pavlotsky F, Amrani S, Trau H . Recurrent erysipelas: risk factors. J Dtsch Dermatol Ges. 2005; 2(2):89-95. DOI: 10.1046/j.1439-0353.2004.03028.x. View

Cox N . Oedema as a risk factor for multiple episodes of cellulitis/erysipelas of the lower leg: a series with community follow-up. Br J Dermatol. 2006; 155(5):947-50. DOI: 10.1111/j.1365-2133.2006.07419.x. View

Karppelin M, Siljander T, Vuopio-Varkila J, Kere J, Huhtala H, Vuento R . Factors predisposing to acute and recurrent bacterial non-necrotizing cellulitis in hospitalized patients: a prospective case-control study. Clin Microbiol Infect. 2009; 16(6):729-34. DOI: 10.1111/j.1469-0691.2009.02906.x. View

10.

Czerniec S, Ward L, Refshauge K, Beith J, Lee M, York S . Assessment of breast cancer-related arm lymphedema--comparison of physical measurement methods and self-report. Cancer Invest. 2009; 28(1):54-62. DOI: 10.3109/07357900902918494. View

11.

Czerniec S, Ward L, Lee M, Refshauge K, Beith J, Kilbreath S . Segmental measurement of breast cancer-related arm lymphoedema using perometry and bioimpedance spectroscopy. Support Care Cancer. 2010; 19(5):703-10. DOI: 10.1007/s00520-010-0896-8. View

12.

Devoogdt N, Lemkens H, Geraerts I, Van Nuland I, Flour M, Coremans T . A new device to measure upper limb circumferences: validity and reliability. Int Angiol. 2010; 29(5):401-7. View

13.

Thomas K, Crook A, Foster K, Mason J, Chalmers J, Bourke J . Prophylactic antibiotics for the prevention of cellulitis (erysipelas) of the leg: results of the UK Dermatology Clinical Trials Network's PATCH II trial. Br J Dermatol. 2011; 166(1):169-78. PMC: 3494300. DOI: 10.1111/j.1365-2133.2011.10586.x. View

14.

OMeara S, Cullum N, Nelson E, Dumville J . Compression for venous leg ulcers. Cochrane Database Syst Rev. 2012; 11:CD000265. PMC: 7068175. DOI: 10.1002/14651858.CD000265.pub3. View

15.

Thomas K, Crook A, Nunn A, Foster K, Mason J, Chalmers J . Penicillin to prevent recurrent leg cellulitis. N Engl J Med. 2013; 368(18):1695-703. DOI: 10.1056/NEJMoa1206300. View

16.

Todd M . Chronic oedema: impact and management. Br J Nurs. 2013; 22(11):623-7. DOI: 10.12968/bjon.2013.22.11.623. View

17.

Inghammar M, Rasmussen M, Linder A . Recurrent erysipelas--risk factors and clinical presentation. BMC Infect Dis. 2014; 14:270. PMC: 4033615. DOI: 10.1186/1471-2334-14-270. View

18.

Chlebicki M, Oh C . Recurrent cellulitis: risk factors, etiology, pathogenesis and treatment. Curr Infect Dis Rep. 2014; 16(9):422. DOI: 10.1007/s11908-014-0422-0. View

19.

Yang Y, Brazier J, Longworth L . EQ-5D in skin conditions: an assessment of validity and responsiveness. Eur J Health Econ. 2014; 16(9):927-39. PMC: 4646948. DOI: 10.1007/s10198-014-0638-9. View

20.

Raff A, Kroshinsky D . Cellulitis: A Review. JAMA. 2016; 316(3):325-37. DOI: 10.1001/jama.2016.8825. View